If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.


Pharmaceutical Chemicals

Novasep and PharmaZell to merge into big drug services firm

by Michael McCoy
September 24, 2021 | A version of this story appeared in Volume 99, Issue 35


The pharmaceutical chemical companies Novasep and PharmaZell are in talks to merge into a new firm that they say would be a leading European contract development and manufacturing organization (CDMO), with annual sales of almost $600 million and about 2,000 employees across seven sites in Europe, two in India, and one in the US. The combined company would be owned by Bridgepoint, the investment firm that owns PharmaZell, a German CDMO that specializes in making complex pharmaceutical chemicals. Novasep, based in France, specializes in complex small molecules and antibody-drug conjugates after selling separation equipment and viral vector businesses earlier this year. Jan Ramakers, a fine chemical consultant in the Netherlands, speculates that Bridgepoint will also sell Novasep’s agrochemical business. Ramakers says the new company will be a major CDMO player in Europe and rank about fifth in sales. Bridgepoint only acquired PharmaZell in May 2020, he notes, but should have sufficient financial power to support the combined firm.


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.